Maraviroc
- Generic Name
- Maraviroc
- Brand Names
- Celsentri, Selzentry
- Drug Type
- Small Molecule
- Chemical Formula
- C29H41F2N5O
- CAS Number
- 376348-65-1
- Unique Ingredient Identifier
- MD6P741W8A
- Background
Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.
- Indication
Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.
- Associated Conditions
- CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients
- Conditions
- AIDSTriple Class FailureHIV-1 Adults Patients
- First Posted Date
- 2009-11-16
- Last Posted Date
- 2010-02-10
- Lead Sponsor
- Fundación Huésped
- Target Recruit Count
- 60
- Registration Number
- NCT01013987
- Locations
- 🇦🇷
Fundación Huésped, Ciudad de Buenos Aires, Argentina
Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1
- Conditions
- HIV-1 InfectionHIV Infections
- Interventions
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 25
- Registration Number
- NCT00993148
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Quest Clinical Research, San Francisco, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients
- Conditions
- Immune Reconstitution Inflammatory SyndromeHIVHIV Infections
- Interventions
- Drug: PlaceboDrug: maraviroc
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Target Recruit Count
- 276
- Registration Number
- NCT00988780
- Locations
- 🇺🇸
NIH/NIAD, Bethesda, Maryland, United States
🇲🇽Hospital General de León, Leon, Guanajuato, Mexico
🇺🇸HIV-1 Immunopathogenesis Laboratory. The Wistar Institute, Philadelphia, Pennsylvania, United States
The Maraviroc Central Nervous System (CNS) Study
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 13
- Registration Number
- NCT00982878
- Locations
- 🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
The St. Marys and The Mater Switch Study
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 18
- Registration Number
- NCT00981773
- Locations
- 🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
🇮🇪Cork University Hospital, Cork, Ireland
🇮🇪Mater Misericordiae University Hospital, Dublin, Ireland
Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- Germans Trias i Pujol Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT00966329
- Locations
- 🇪🇸
Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain
🇪🇸Lluita contra la Sida Foundation, HIV Unit, Badalona, Barcelona, Spain
🇪🇸Lluita contra la Sida Foundation, HIV Unit, Irsi Caixa Foundation, Badalona, Barcelona, Spain
Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration
- Conditions
- HIV InfectionHIV Infections
- First Posted Date
- 2009-07-23
- Last Posted Date
- 2011-12-22
- Lead Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
- Target Recruit Count
- 60
- Registration Number
- NCT00944541
- Locations
- 🇫🇷
French National Agency for Research on AIDS and Viral Hepatits, Paris, France
CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 32
- Registration Number
- NCT00925756
- Locations
- 🇺🇸
Harbor-UCLA, Torrance, California, United States
🇺🇸University California San Diego, San Diego, California, United States
🇺🇸University Southern California, Los Angeles, California, United States
Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2013-04-30
- Lead Sponsor
- ASST Fatebenefratelli Sacco
- Target Recruit Count
- 100
- Registration Number
- NCT00884858
- Locations
- 🇮🇹
Servizio Regionale di Immunologia Clinica e Tipizzazione Tissutale, Azienda Ospedaliero-Universitaria, Torrette di Ancona, AN, Italy
🇮🇹Clinica di Malattie Infettive, Policlinico, Universita' degli Studi, Bari, BA, Italy
🇮🇹Clinica di Malattie Infettive e Tropicali, Università degli Studi di Brescia, Spedali civili, Brescia, BS, Italy
Maraviroc Immune Recovery Study
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2013-09-10
- Lead Sponsor
- S.F.L. van Lelyveld
- Target Recruit Count
- 85
- Registration Number
- NCT00875368
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇳🇱Sint Elisabeth Ziekenhuis, Tilburg, Netherlands
🇳🇱Academisch Medisch Centrum (AMC), Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.